BioSpace News Archive

Silk Medical Aesthetics, Inc., a spin-off of the green chemistry company Evolved By Nature, today announces receipt of FDA IDE approval to initiate a human clinical trial of the industry’s first all-natural, silk-based dermal filler.

Immediate order for 1,500 additional spencer® devices for Catalyst Healthcare’s network to connect through telehealth with Canada’s most vulnerable patients

Parallax Health Sciences, Inc. (OTCQB: PRLX) (“Parallax” or the “Company”), an outcome-driven connected healthcare company, today announced that its Parallax Health Management and Parallax Diagnostics divisions have added customer accounts within the U.S. healthcare industry.

AzurRx BioPharma, Inc. today announced the appointment of Gregory Oakes to the Board of Directors effective April 13, 2020. “Greg is a strong and welcomed addition to our board,” said James Sapirstein, CEO of AzurRx BioPharma. “His broad experience in pharmaceutical commercialization and acqui

Celularity Inc. (“Celularity” or the “Company”), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation’s (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).

What’s New: Intel and the Georgia Institute of Technology announced that they have been selected to lead a Guaranteeing Artificial Intelligence Robustness against Deception program team for the Defense Advanced Research Projects Agency.

Trinity Life Sciences, a leader in global life sciences solutions, and Toluna, a leading consumer intelligence platform that delivers insights on demand, announced the availability of a new brief regarding the impact of COVID-19 on healthcare market research.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that in its patent litigation against Boston Scientific the U.S. Court of Appeals for the Federal Circuit issued a ruling in its favor.

In response to Covid-19, the LSU Health Network will be the first healthcare system in the southeast to bring Ninety One’s advanced algorithms and technologies to assist with analysis of complex medical data for cardiology patients.